OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer
Pierre Loap, Delphine Loirat, Frédérique Berger, et al.
JAMA Oncology (2022) Vol. 8, Iss. 12, pp. 1802-1802
Open Access | Times Cited: 47
Pierre Loap, Delphine Loirat, Frédérique Berger, et al.
JAMA Oncology (2022) Vol. 8, Iss. 12, pp. 1802-1802
Open Access | Times Cited: 47
Showing 1-25 of 47 citing articles:
Molecular mechanisms of tumor resistance to radiotherapy
Yu Wu, Yingqiu Song, Runze Wang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 176
Yu Wu, Yingqiu Song, Runze Wang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 176
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
Icro Meattini, Carlotta Becherini, Saverio Caini, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 2, pp. e73-e83
Open Access | Times Cited: 27
Icro Meattini, Carlotta Becherini, Saverio Caini, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 2, pp. e73-e83
Open Access | Times Cited: 27
Results of a phase Ib study of olaparib with concomitant radiotherapy in soft-tissue sarcoma: a French sarcoma group study
Paul Sargos, M.-P. Sunyach, A. Ducassou, et al.
Annals of Oncology (2025)
Open Access | Times Cited: 1
Paul Sargos, M.-P. Sunyach, A. Ducassou, et al.
Annals of Oncology (2025)
Open Access | Times Cited: 1
Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions
Denys Bondar, Yevgen Karpichev
Biomolecules (2024) Vol. 14, Iss. 10, pp. 1269-1269
Open Access | Times Cited: 7
Denys Bondar, Yevgen Karpichev
Biomolecules (2024) Vol. 14, Iss. 10, pp. 1269-1269
Open Access | Times Cited: 7
Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial
Céline Callens, Manuel Rodrigues, Adrien Briaux, et al.
Oncogene (2023) Vol. 42, Iss. 48, pp. 3556-3563
Open Access | Times Cited: 15
Céline Callens, Manuel Rodrigues, Adrien Briaux, et al.
Oncogene (2023) Vol. 42, Iss. 48, pp. 3556-3563
Open Access | Times Cited: 15
PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities
Wenhao Li, Fei Wang, Gui-yuan Song, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 13
Wenhao Li, Fei Wang, Gui-yuan Song, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 13
PARP inhibitors combined with radiotherapy: are we ready?
Chen Sun, Alan Chu, Rui Song, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 13
Chen Sun, Alan Chu, Rui Song, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 13
BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy
Sushmitha Sriramulu, Shivani Thoidingjam, Farzan Siddiqui, et al.
Biomolecules (2024) Vol. 14, Iss. 6, pp. 625-625
Open Access | Times Cited: 4
Sushmitha Sriramulu, Shivani Thoidingjam, Farzan Siddiqui, et al.
Biomolecules (2024) Vol. 14, Iss. 6, pp. 625-625
Open Access | Times Cited: 4
Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer
Yijun Xie, Di Xiao, Duo Li, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Yijun Xie, Di Xiao, Duo Li, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Survival and prognostic factors in non-metastatic chemorefractory inflammatory breast cancer: a comprehensive population-based study
Pierre Loap, Youlia Kirova
Clinical Oncology (2025) Vol. 39, pp. 103756-103756
Closed Access
Pierre Loap, Youlia Kirova
Clinical Oncology (2025) Vol. 39, pp. 103756-103756
Closed Access
BRCAness Identifies Synthetic Cytotoxicity Between Cisplatin and Radiation Therapy
Kerstin Borgmann, David Krug
International Journal of Radiation Oncology*Biology*Physics (2025) Vol. 121, Iss. 3, pp. 780-782
Closed Access
Kerstin Borgmann, David Krug
International Journal of Radiation Oncology*Biology*Physics (2025) Vol. 121, Iss. 3, pp. 780-782
Closed Access
Progress in the Application of Nanomaterials for Radio Sensitization in Tumor Radiotherapy
淞名 吴
Advances in Clinical Medicine (2025) Vol. 15, Iss. 01, pp. 1963-1971
Closed Access
淞名 吴
Advances in Clinical Medicine (2025) Vol. 15, Iss. 01, pp. 1963-1971
Closed Access
Enhancing Radiation Therapy with PARP Inhibition in Soft Tissue Sarcomas: A Promising Synergy Requiring Specific Attention to Normal Tissues?
Antonin Lévy, Céline Clémenson, Michele Mondini, et al.
Annals of Oncology (2025)
Closed Access
Antonin Lévy, Céline Clémenson, Michele Mondini, et al.
Annals of Oncology (2025)
Closed Access
Novel clinical potential of poly (ADP‑ribose) polymerase inhibitors in triple‑negative breast cancer: Mechanistic insights and clinical applications (Review)
Han Yu, Lei Wei
Oncology Letters (2025) Vol. 29, Iss. 5, pp. 1-14
Open Access
Han Yu, Lei Wei
Oncology Letters (2025) Vol. 29, Iss. 5, pp. 1-14
Open Access
Neoadjuvant Strategies for Triple Negative Breast Cancer: Current Evidence and Future Perspectives
Zhenjun Huang, Qing Peng, Luhui Mao, et al.
MedComm – Future Medicine (2025) Vol. 4, Iss. 1
Open Access
Zhenjun Huang, Qing Peng, Luhui Mao, et al.
MedComm – Future Medicine (2025) Vol. 4, Iss. 1
Open Access
Design and synthesis of phenanthridinone and phenanthridine derivatives and their radiosensitizing activity
Wenya Liu, Chuansheng Yao, Y. LI, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 123, pp. 118161-118161
Closed Access
Wenya Liu, Chuansheng Yao, Y. LI, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 123, pp. 118161-118161
Closed Access
Advances in PSMA-Targeted Radionuclide Therapeutics
Samuel Ruder, Andrés Ricaurte-Fajardo, Michael Sun, et al.
Current Treatment Options in Oncology (2025)
Closed Access
Samuel Ruder, Andrés Ricaurte-Fajardo, Michael Sun, et al.
Current Treatment Options in Oncology (2025)
Closed Access
Parp Inhibitors and Radiotherapy: A New Combination for Prostate Cancer (Systematic Review)
I. Rivero Belenchón, Carmen Belen Congregado Ruiz, Carmen Sáez, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12978-12978
Open Access | Times Cited: 10
I. Rivero Belenchón, Carmen Belen Congregado Ruiz, Carmen Sáez, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12978-12978
Open Access | Times Cited: 10
Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer
Rosa Bellavita, Marialuisa Piccolo, Linda Leone, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 6057-6084
Open Access | Times Cited: 3
Rosa Bellavita, Marialuisa Piccolo, Linda Leone, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 6057-6084
Open Access | Times Cited: 3
Role of AURKB Inhibition in Reducing Proliferation and Enhancing Effects of Radiotherapy in Triple-Negative Breast Cancer
Sierra Pellizzari, Harjot Athwal, Anne C. Bonvissuto, et al.
Breast Cancer Targets and Therapy (2024) Vol. Volume 16, pp. 341-346
Open Access | Times Cited: 2
Sierra Pellizzari, Harjot Athwal, Anne C. Bonvissuto, et al.
Breast Cancer Targets and Therapy (2024) Vol. Volume 16, pp. 341-346
Open Access | Times Cited: 2
Current status and prospect of the DNA double-strand break repair pathway in colorectal cancer development and treatment
Kexin Yang, Li Zhu, Chang Liu, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 7, pp. 167438-167438
Closed Access | Times Cited: 2
Kexin Yang, Li Zhu, Chang Liu, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 7, pp. 167438-167438
Closed Access | Times Cited: 2
Development and validation of a sensitive LC–MS/MS method for the assay of four PARP inhibitors in human plasma and its application in ovarian cancer patients
Yuru Wei, Haixi Liang, Shu Liu, et al.
Journal of Pharmaceutical and Biomedical Analysis (2023) Vol. 237, pp. 115758-115758
Closed Access | Times Cited: 5
Yuru Wei, Haixi Liang, Shu Liu, et al.
Journal of Pharmaceutical and Biomedical Analysis (2023) Vol. 237, pp. 115758-115758
Closed Access | Times Cited: 5
A review of therapeutic agents for breast cancer with potentially radiosensitizing properties
Zhongwei Zhang, David Lim, Zhihui Feng
Radiation Medicine and Protection (2024) Vol. 5, Iss. 2, pp. 75-82
Open Access | Times Cited: 1
Zhongwei Zhang, David Lim, Zhihui Feng
Radiation Medicine and Protection (2024) Vol. 5, Iss. 2, pp. 75-82
Open Access | Times Cited: 1
Revolutionizing Breast Cancer Care: Cutting-Edge Breakthroughs and Future Frontiers in Precision Medicine
Muhammad Ali Qureshi, Muhammad Younas Khan, Ahmed Imran, et al.
(2024), pp. 115-141
Closed Access | Times Cited: 1
Muhammad Ali Qureshi, Muhammad Younas Khan, Ahmed Imran, et al.
(2024), pp. 115-141
Closed Access | Times Cited: 1
Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review
Lucía Serrano-García, Beatriz Jávega, Antonio Llombart‐Cussac, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Lucía Serrano-García, Beatriz Jávega, Antonio Llombart‐Cussac, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
